A randomized add-on trial of an N -methyl-D-aspartate antagonist in treatment-resistant bipolar depression
'In accordance with the increasing patient population, it is highly likely that a number of companies manufacturing these later entrants will receive great returns for their efforts.' Expected to hit the market in 2025, Novos CagriSema alone will likely garner $7.4 billion in sales by 2029
This expanded report evaluates pharmacokinetics,receptor biology, clinical trial methodology, New Neuroactive GLP Medicines: Brain-Targeted Metabolic Research February 11, 2026 Introduction GLP Research Is No Longer Just About Blood Sugar For over a decade, glucagon-like peptide (GLP)based compounds have been studied primarily for their effects on glucose regulation, insulin signaling, and peripheral metabolic pathways
mansoni (lower pathway), TrxR and GR are replaced with a unique oxidoreductase flavoenzyme, TGR, which provides reducing equivalents for Trx-, GSH- and Grx-dependent reactions